RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More
In Silico Structure-based Drug Design - Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement… Read More
TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More
Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More
Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More
By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More
Lead Generation and Lead Optimisation: the value of linking HT co-structure analysis and HT chemistry By Dr David U Prichard The coupling of High Throughput co-structure analysis with focused library generation is not only proving a powerful general tool in lead optimisation but also increasing the probability of successful discovery… Read More
By Dr Mark L. Nelson Less than a hundred years ago, if you developed a microbial infection your immune system couldnt handle, you died. Then came the wonder drugs, antibiotics capable of fighting the infections for you. But times have changed. Now, because of antibiotics, their use and misuse, the… Read More
Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More
Proteomics In Drug Target Discovery - High-throughput meets high-efficiency By Dr Terence E. Ryan and Dr Scott D. Patterson Biochemistry is enjoying a renaissance under the guise of 'proteomics' due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and… Read More
Silicon Technology and Pharmaceutics by Professor Leigh T. Canham, Dr Roghieh S. Saffie, Stephen E. Connor and Dr Roger Aston The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as a whole. Read More
Chemogenomics - A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts… Read More
Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More
Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More
High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by the exorbitant costs of discovery and clinical… Read More
The Industrialisation of Bioinformatics By Dr Alex Titomirov With the completion of the ‘draft’ sequence of the human genome predicting an estimate of 40,000-120,000 genes that describe us, the real work begins. The problem now is not lack of data but lack of tools to thoroughly analyse what we already… Read More